In Asia, there is a need for agents to treat chronic angle closure glaucoma. This article highlights factors in determining whether to conduct an active or placebo control study and special circumstances that increase the complexity of this decision in clinical trials for chronic angle glaucoma trials. The authors advise the use of a placebo control design in pivotal clinical trials dealing with chronic angle closure glaucoma. Once a medication is approved for use in chronic angle closure glaucoma, subsequent pivotal trials of similar drugs can use an active control design.
FosterPJBaasanhuJAlsbirkPHGlaucoma in Mongolia. A population-based survey in Hovsgol province, northern Mongolia. Arch Ophthalmol.1996;114:1235–1241.
2.
SpilkerB. Controls used in clinical trials. In: SpilkerB, ed. Guide to Clinical Trials.New York: Raven Press; 1991:59–68.
3.
AuntTWongHTYipCCComparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma. Opthalmology.2000;107:1178–1183.
4.
StrahlmanETippingRVogelR. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide dose-response study group. Am J Ophthalmol.1996;122:183–194.
5.
WilkersonMCyrlinMLippaEAFour week safety and efficacy study of dorzolamide, a novel active topical carbonic anhydrase inhibitor. Arch Ophthalmol.1993;111:1343–1350.
6.
SallK. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Asopt) as a primary therapy in patients with open angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol.2000;44:S155–162.
7.
ParisiVManniGColacinoGCytidine-5′-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology.1999;106:1126–1134.
8.
DerickRJRobinALWaltersTRBrimonidine tartrate: a one month dose response study. Ophthalmology.1997;104:131–136.
